Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
43
TLPPF Quote, Financials, Valuation and Earnings
Last price:
$9.16
Seasonality move
:
30.39%
Day range:
$9.16 - $9.16
52-week range:
$8.56 - $24.85
Dividend yield:
0%
P/E ratio:
295.48x
P/S ratio:
4.75x
P/B ratio:
25.94x
Volume:
113
Avg. volume:
1.3K
1-year change:
-42.9%
Market cap:
$3.1B
Revenue:
$516.6M
EPS (TTM):
$0.03
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Telix Pharmaceuticals Ltd. has -- downside to fair value with a price target of -- per share.
TLPPF vs. S&P 500
-
Over the past 5 trading days, Telix Pharmaceuticals Ltd. has underperformed the S&P 500 by -6.39% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Telix Pharmaceuticals Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Telix Pharmaceuticals Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Telix Pharmaceuticals Ltd. reported revenues of --.
Earnings Growth
-
Telix Pharmaceuticals Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Telix Pharmaceuticals Ltd. reported earnings per share of --.
Enterprise value:
3B
EV / Invested capital:
--
Price / LTM sales:
4.75x
EV / EBIT:
98.73x
EV / Revenue:
4.49x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-113.72x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
70.04x
Gross Profit (TTM):
$388.2M
Return On Assets:
4.54%
Net Income Margin (TTM):
1.66%
Return On Equity:
13.56%
Return On Invested Capital:
6.6%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2023-03-31 | 2024-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $115M | |
| Gross Profit | -- | -- | -- | -- | $75.9M | |
| Operating Income | -- | -- | -- | -- | $20.4M | |
| EBITDA | -- | -- | -- | -- | $21.3M | |
| Diluted EPS | -- | -- | -- | -- | $0.04 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $52.8M | $102.8M | $145.2M | $170.6M | -- | |
| Total Assets | $96.8M | $148.5M | $205.4M | $498.6M | -- | |
| Current Liabilities | $16.7M | $32M | $94.4M | $172.7M | -- | |
| Total Liabilities | $60.8M | $76M | $155.1M | $228.6M | -- | |
| Total Equity | $36M | $72.5M | $50.3M | $270M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2023-03-31 | 2024-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | $3.6M | |
| Cash From Investing | -- | -- | -- | -$1.1M | -$5.9M | |
| Cash From Financing | -- | -- | -- | $1.3M | -$963K | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
TLPPF
Sector
Market Cap
$3.1B
$28.5M
Price % of 52-Week High
36.86%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
0.17%
-1.33%
1-Year Price Total Return
-42.9%
-20.32%
Beta (5-Year)
2.101
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$9.35
200-day SMA
Sell
Level
$13.78
Bollinger Bands (100)
Sell
Level
8.92 - 12.34
Chaikin Money Flow
Buy
Level
720K
20-day SMA
Sell
Level
$9.44
Relative Strength Index (RSI14)
Sell
Level
43.73
ADX Line
Sell
Level
14.04
Williams %R
Neutral
Level
-67.2897
50-day SMA
Sell
Level
$9.80
MACD (12, 26)
Sell
Level
-0.21
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
1.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.0838)
Sell
CA Score
(Annual)
Level (-0.3314)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (0.1994)
Buy
Piotroski F Score
(Annual)
Level (6)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Stock Forecast FAQ
In the current month, TLPPF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TLPPF average analyst price target in the past 3 months is --.
-
Where Will Telix Pharmaceuticals Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Telix Pharmaceuticals Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Telix Pharmaceuticals Ltd.?
Analysts are divided on their view about Telix Pharmaceuticals Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Telix Pharmaceuticals Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Telix Pharmaceuticals Ltd.'s Price Target?
The price target for Telix Pharmaceuticals Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TLPPF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Telix Pharmaceuticals Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of TLPPF?
You can purchase shares of Telix Pharmaceuticals Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Telix Pharmaceuticals Ltd. shares.
-
What Is The Telix Pharmaceuticals Ltd. Share Price Today?
Telix Pharmaceuticals Ltd. was last trading at $9.16 per share. This represents the most recent stock quote for Telix Pharmaceuticals Ltd.. Yesterday, Telix Pharmaceuticals Ltd. closed at $9.16 per share.
-
How To Buy Telix Pharmaceuticals Ltd. Stock Online?
In order to purchase Telix Pharmaceuticals Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get TLPPF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TLPPF
Sector
P/E ratio
295.48x
23.75x
PEG ratio
--
-0.01x
P/B ratio
25.94x
1.83x
Price / LTM sales
4.75x
1.60x
Growth Metrics
TLPPF
Sector
Revenue growth
--
4.85%
Earnings growth
--
11.11%
Revenue (5-year growth)
192.28%
6.45%
Earnings forecast
--
-$0.20
Profitability
TLPPF
Sector
Profitability FY 2024
$336.6M
$3.6M
Return on invested capital
6.6%
-30.98%
Return on assets
4.54%
-27.62%
Return on equity
13.56%
-36.69%
Earnings Date
Last Earnings Date
Aug
20
Next Earnings Date
Feb
19
Estimated Next Earnings Date
Nov
19
Balance Sheet
TLPPF
Sector
Total cash
$441.7M
$27.2M
Short term investments
--
$25.7M
Total assets
$944.9M
$79.7M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
